Clinical Trials Logo
  1. Home
  2. T-Cell Lymphoma
  3. NCT05075460

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

T-cell Lymphoma Clinical Trial

Official title:
A Prospective, Multicenter, Phase III, Non-randomized Study of Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Clinical Trial Summary

This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma

Clinical Trial Description

Tucidinostat, a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. Azacytidine is a hypomethylating agent. The aim of this study is to compare the efficacy and safety of azacytidine, tucidinostat combined with CHOP regimen and classical CHOP regimen in the treatment of primary PTCL ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05075460
Study type Interventional
Source Peking Union Medical College Hospital
Contact Yan Zhang
Phone +861069156874
Email zhangyan10659@pumch.cn
Status Recruiting
Phase Phase 3
Start date October 1, 2021
Completion date October 30, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT00959686 - Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma Phase 2
Active, not recruiting NCT04712864 - Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma Phase 1
Recruiting NCT05665530 - A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies Phase 1
Completed NCT01941680 - High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Completed NCT03734601 - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Phase 2
Completed NCT02017613 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Phase 1
Enrolling by invitation NCT01854112 - Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma N/A
Completed NCT01553786 - Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) Phase 2
Completed NCT00542919 - A Study for Patients With Non-Hodgkin's Lymphomas Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Active, not recruiting NCT03952078 - A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Phase 1
Not yet recruiting NCT05983965 - Study of Tazemetostat in Lymphoid Malignancies Phase 1
Not yet recruiting NCT06390319 - Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Phase 2
Not yet recruiting NCT05387226 - Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma Phase 1
Completed NCT02424045 - Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Phase 2
Completed NCT01871675 - Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Phase 1
Terminated NCT00893516 - CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Phase 2
Completed NCT01902225 - Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT02086591 - A Phase II Study of Doxycycline in Relapsed NHL Phase 2
Recruiting NCT04264078 - Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Early Phase 1